Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

Preparing for antic­i­pat­ed launch of lead com­pound for DMD

Leiden, The Netherlands, June 30, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, today announced the appoint­ment of Willem W. van Weperen to the new posi­tion of chief com­mer­cial offi­cer and the addi­tion of Dr. Annalisa Jenkins to its Supervisory Board.
With more than two decades of expe­ri­ence at Genzyme and GSK and his recent lead­er­ship of Dutch to-BBB as CEO, Mr. van Weperen brings sig­nif­i­cant busi­ness oper­a­tional and com­mer­cial exper­tise to Prosensa in advance of an antic­i­pat­ed launch of the company’s first prod­uct for the treat­ment of Duchenne mus­cu­lar dys­tro­phy (DMD).
Hans Schikan, CEO of Prosensa said, “We expect Willem to play a crit­i­cal role at Prosensa as we move from a research and devel­op­ment stage com­pa­ny to a com­mer­cial orga­ni­za­tion. His knowl­edge and expe­ri­ence will be invalu­able as we build the infra­struc­ture to sup­port the antic­i­pat­ed launch of our first prod­uct for treat­ing boys with DMD.”
Prior to his role at to-BBB, Mr. van Weperen spent 15 years at Genzyme in a num­ber of senior man­age­ment and com­mer­cial posi­tions at both a nation­al and inter­na­tion­al lev­el. He joined Genzyme in 1994 as med­ical affairs man­ag­er in Europe. Subsequently, he worked as Area Manager Therapeutics for the Benelux, respon­si­ble for sales and mar­ket­ing of Genzyme’s orphan dis­ease prod­ucts fol­low­ing which he took on the role as European Marketing Director for the Company’s LSD/Thyrogen prod­ucts. Since 2003, he assumed glob­al respon­si­bil­i­ty for mar­ket­ing in the rare genet­ic dis­ease busi­ness unit in Genzyme’s world­wide head­quar­ters in Cambridge, MA. Most recent­ly, he led Genzyme’s Netherlands orga­ni­za­tion in Naarden. At Genzyme, he over­saw and sig­nif­i­cant­ly con­tributed to sev­er­al glob­al launch­es of prod­ucts in the company’s rare dis­ease port­fo­lio.
“I’m thrilled to be join­ing Prosensa at such an excit­ing and piv­otal time for the com­pa­ny and look for­ward to apply­ing my exper­tise in com­mer­cial­iz­ing rare dis­ease drugs to poten­tial­ly launch­ing one of the first prod­ucts to treat DMD,” said Mr. van Weperen.
Dr. Jenkins joins Prosensa’s Supervisory Board with more than 25 years of expe­ri­ence in the health­care sec­tor. In her most recent role as Head of Global Research and Development and Executive Vice President at Merck Serono, which she has held since October 2013, she was respon­si­ble for build­ing glob­al devel­op­ment, research and med­ical capa­bil­i­ties, span­ning research, devel­op­ment, glob­al reg­u­la­to­ry and clin­i­cal devel­op­ment in addi­tion to med­ical affairs and patient access. She joined the com­pa­ny in 2011, pre­vi­ous­ly serv­ing as Executive Vice President Global Development and Medical. Prior to join­ing Merck Serono, Dr. Jenkins held var­i­ous region­al and glob­al roles with Bristol-Myers Squibb since 1997, most recent­ly as Senior Vice President, Global Medical Affairs.
“We are delight­ed to wel­come Annalisa to Prosensa’s Supervisory Board. Her exten­sive expe­ri­ence in research and clin­i­cal devel­op­ment and med­ical affairs for Merck Serono and Bristol Myers Squibb, which are amongst the top phar­ma com­pa­nies in the world, will bring valu­able insights to us as we take the com­pa­ny to the next lev­el,” said David Mott, Chairman of the Supervisory Board at Prosensa.
Dr. Jenkins began her career as a Medical Officer with the British Royal Navy after grad­u­at­ing in Medicine from St. Bartholomew’s Hospital London and train­ing in Cardiovascular Medicine in the UK National Health Service.
“I am excit­ed to join Prosensa at such a sig­nif­i­cant moment in the company’s his­to­ry and look for­ward to work­ing along­side a world-class team with excep­tion­al lead­er­ship in rare dis­eases,” said Dr. Jenkins. “With such an exten­sive research and devel­op­ment pipeline in DMD, I hope to inte­grate my exper­tise in glob­al R&D as Prosensa con­tin­ues to advance its port­fo­lio of inno­v­a­tive exon-skip­ping tech­nol­o­gy.”
The appoint­ment of Dr. Annalisa Jenkins will be sub­ject to share­hold­ers’ approval at the next share­hold­ers’ meet­ing, sched­uled for August 20, 2014.

Leave a Reply

Your email address will not be published. Required fields are marked *